Globus Medical Reports Strong Preliminary Q4 & FY25 Sales, Issues Positive 2026 Guidance
Summary
Globus Medical announced robust preliminary sales for Q4 and full-year 2025, exceeding expectations with significant growth, and provided optimistic revenue and EPS guidance for 2026.
Key Events
-
Strong Preliminary 2025 Sales
Globus Medical reported preliminary Q4 2025 sales of approximately $823.2 million, a 25.2% increase over the prior year, and full-year 2025 sales of $2.936 billion, up 16.5%.
-
Positive 2026 Guidance Issued
The company established full-year 2026 revenue guidance between $3.18 billion and $3.22 billion, with non-GAAP diluted earnings per share projected at $4.30 to $4.40.
-
Successful Acquisition Integration
Management highlighted strong momentum and successful integration of the NuVasive and Nevro acquisitions, contributing to above-market growth.
Analysis
The preliminary unaudited results indicate strong operational performance and successful integration of recent acquisitions, particularly Nevro. The substantial year-over-year sales growth in Q4 and for the full year 2025, coupled with positive revenue and earnings per share guidance for 2026, suggests continued momentum and market share gains. This update provides investors with a confident outlook for the company's financial health and future growth trajectory, reinforcing the stock's current position near its 52-week high.
At the time of this filing, GMED was trading at $98.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.2B. The 52-week trading range was $51.79 to $94.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.